Amneal Pharmaceuticals Inc (NYSE:AMRX) disclosed on Friday the receipt of the US FDA approval for the generic version of BiCNU (carmustine) for injection in 100 mg.
In conjunction, the company plans to launch its Carmustine for Injection in November 2018. Carmustine is a medication used mainly for chemotherapy.
For the 12 months ended August 2018, the US market annual sales for Carmustine for Injection USP in 100 mg/vial is estimated to be about USD84m, according to IQVIA.
Headquartered in Bridgewater, NJ, the specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream